Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Xenon-129 fMRI in Alzheimer's Disease
NCT02638519Phase 1Terminated
- Sponsor
- Thunder Bay Regional Health Research Institute
- Start
- Jun 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hyperpolarized xenon gas in Alzheimer's disease (AD) (2 arms), sponsored by Thunder Bay Regional Health Research Institute. Primary endpoint: Signal-to-Noise Ratio at 3 years. Started Jun 2016; status: terminated.
02
Drugs
hyperpolarized xenon gas
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02638519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638519.